Prognostic and Clinical Significance of the Proliferation Marker MCM7 in Breast Cancer
Pathobiology · 27.08.2024 · 1-10
DOI: 10.1159/000540790 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathobiology, online erschienen am 27.08.2024. Verfasst von Ayat G Lashen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK, ayat.lashen1@nottingham.ac.uk. Hauptthemen laut MEDLINE: Minichromosome Maintenance Complex Component 7, Breast Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Minichromosome maintenance complex component 7 (MCM7) plays an essential role in proliferation and DNA replication of cancer cells. However, the expression and prognostic significance of MCM7 in breast cancer (BC) remain to be defined. In this study, we aimed to evaluate the role of MCM7 in BC.
Methods
We conducted immunohistochemistry staining of MCM7 in 1,156 operable early-stage BC samples and assessed MCM7 at the transcriptomic levels using publicly available cohorts (n = 13,430). MCM7 expression was evaluated and correlated with clinicopathological parameters including Ki67 labelling index and patient outcome.
Results
At the transcriptomic level, there was a significant association between high MCM7 mRNA levels and shorter patient survival in the whole cohort and in luminal BC class but not in the basal-like molecular subtype. High MCM7 protein expression was detected in 43% of patients and was significantly associated with parameters characteristic of aggressive tumour behaviour. MCM7 was independently associated with shorter survival, particularly in oestrogen receptor-positive (luminal) BC. MCM7 stratified luminal tumours with aggressive clinicopathological features into distinct prognostic groups. In endocrine therapy-treated BC patients, high MCM7 was associated with poor outcome, but such association disappeared with administration of adjuvant chemotherapy. Patients with high expression of Ki67 and MCM7 showed worst survival, while patients with double low expression BC showed the best outcome compared with single expression groups.
Conclusion
The current findings indicate that MCM7 expression has a prognostic value in BC and can be used to identify luminal BC patients who can benefit from adjuvant chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK, ayat.lashen1@nottingham.ac.uk.
- Department of Pathology, Faculty of Medicine, Menoufia University, Shebeen El Kom, Egypt, ayat.lashen1@nottingham.ac.uk.
- Nottingham Breast Cancer Research Centre, University of Nottingham, Nottingham, UK, ayat.lashen1@nottingham.ac.uk.
- Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK.
- Nottingham Breast Cancer Research Centre, University of Nottingham, Nottingham, UK.
- Department of Histopathology, Sheffield Teaching Hospitals NHS Foundation Trust Sheffield, Sheffield, UK.
Zitieren
APA
Lashen, A. G., Toss, M. S., Rutland, C. S., Green, A. R., Mongan, N. P., & Rakha, E. (2024). Prognostic and Clinical Significance of the Proliferation Marker MCM7 in Breast Cancer. Pathobiology, 1-10. https://doi.org/10.1159/000540790
Vancouver
Lashen AG, Toss MS, Rutland CS, Green AR, Mongan NP, Rakha E. Prognostic and Clinical Significance of the Proliferation Marker MCM7 in Breast Cancer. Pathobiology. 2024:1-10. doi:10.1159/000540790
BibTeX
@article{Lashen2024,
author = {Lashen, Ayat G and Toss, Michael S and Rutland, Catrin S and Green, Andrew R and Mongan, Nigel P and Rakha, Emad},
title = {Prognostic and Clinical Significance of the Proliferation Marker MCM7 in Breast Cancer},
journal = {Pathobiology},
year = {2024},
pages = {1--10},
doi = {10.1159/000540790}
}
EUVIMED